These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 29724296)

  • 21. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
    Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
    ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genes affecting warfarin response-interactive or additive?
    Cavallari LH; Duarte JD
    J Clin Pharmacol; 2015 Mar; 55(3):258-60. PubMed ID: 25385663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.
    Lee K; Woo HI; Bang OY; On YK; Kim JS; Lee SY
    Clin Pharmacokinet; 2015 May; 54(5):517-25. PubMed ID: 25466603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of genetic polymorphisms and non-genetic factors on the maintenance dose of warfarin].
    Hou J; Dong X; Wang Y; Wang G; Dong L; Li-Ling J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):629-34. PubMed ID: 26418980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.
    Topkara VK; Knotts RJ; Jennings DL; Garan AR; Levin AP; Breskin A; Castagna F; Cagliostro B; Yuzefpolskaya M; Takeda K; Takayama H; Uriel N; Mancini DM; Eisenberger A; Naka Y; Colombo PC; Jorde UP
    ASAIO J; 2016; 62(5):558-64. PubMed ID: 27258224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool.
    Saffian SM; Duffull SB; Roberts RL; Tait RC; Black L; Lund KA; Thomson AH; Wright DF
    Ther Drug Monit; 2016 Dec; 38(6):677-683. PubMed ID: 27855133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin, genes, and the (health care) environment.
    Kazi DS; Hlatky MA
    JAMA Intern Med; 2014 Aug; 174(8):1338-9. PubMed ID: 24934523
    [No Abstract]   [Full Text] [Related]  

  • 37. Genotype and risk of major bleeding during warfarin treatment.
    Kawai VK; Cunningham A; Vear SI; Van Driest SL; Oginni A; Xu H; Jiang M; Li C; Denny JC; Shaffer C; Bowton E; Gage BF; Ray WA; Roden DM; Stein CM
    Pharmacogenomics; 2014 Dec; 15(16):1973-83. PubMed ID: 25521356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the role of pharmacogenetics in optimization of warfarin dosing?
    Carnes CA
    Trends Cardiovasc Med; 2015 Jan; 25(1):42-3. PubMed ID: 25476743
    [No Abstract]   [Full Text] [Related]  

  • 39. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.
    Grossi E; Podda GM; Pugliano M; Gabba S; Verri A; Carpani G; Buscema M; Casazza G; Cattaneo M
    Pharmacogenomics; 2014 Jan; 15(1):29-37. PubMed ID: 24329188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.
    Santos PC; Marcatto LR; Duarte NE; Gadi Soares RA; Cassaro Strunz CM; Scanavacca M; Krieger JE; Pereira AC
    Pharmacogenomics; 2015 Jul; 16(8):865-76. PubMed ID: 26050796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.